ibrutinib + dexamethasone

**Ibrutinib + dexamethasone** is a combination of an irreversible Bruton’s tyrosine kinase (BTK) inhibitor (ibrutinib) and a synthetic glucocorticoid corticosteroid (dexamethasone) used in clinical studies for relapsed or refractory multiple myeloma and other B-cell–mediated hematological malignancies. - **Ibrutinib** selectively and covalently binds BTK, a kinase that mediates B-cell receptor signaling, leading to decreased cell survival and proliferation and increased apoptosis in malignant B-cells. It also inhibits interleukin-2 inducible kinase (ITK) in T cells and affects PI3K signaling[2][8][6]. - **Dexamethasone** binds and activates the glucocorticoid receptor, modulating gene expression and producing anti-inflammatory, immunosuppressive, and apoptotic effects. Primary indications in combination trials have included treatment of relapsed/refractory multiple myeloma, with data indicating enhanced apoptosis of myeloma cells via PI3K/PARP pathway and complementary anti-myeloma activity[4][3][5].

Other names

ibrutinib and dexamethasone